Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Rurangirwa J[original query] |
---|
Cost implications of HIV retesting for verification in Africa
Lasry A , Kalou MB , Young PR , Rurangirwa J , Parekh B , Behel S . PLoS One 2019 14 (7) e0218936 INTRODUCTION: HIV misdiagnosis leads to severe individual and public health consequences. Retesting for verification of all HIV-positive cases prior to antiretroviral therapy initiation can reduce HIV misdiagnosis, yet this practice has not been not widely implemented. METHODS: We evaluated and compared the cost of retesting for verification of HIV seropositivity (retesting) to the cost of antiretroviral treatment (ART) for misdiagnosed cases in the absence of retesting (no retesting), from the perspective of the health care system. We estimated the number of misdiagnosed cases based on a review of misdiagnosis rates, and the number of positives persons needing ART initiation by 2020. We presented the total and per person costs of retesting as compared to no retesting, over a ten-year horizon, across 50 countries in Africa grouped by income level. We conducted univariate sensitivity analysis on all model input parameters, and threshold analysis to evaluate the parameter values where the total costs of retesting and the costs no retesting are equivalent. Cost data were adjusted to 2017 United States Dollars. RESULTS AND DISCUSSION: The estimated number of misdiagnoses, in the absence of retesting was 156,117, 52,720 and 29,884 for lower-income countries (LICs), lower-middle income countries (LMICs), and upper middle-income countries (UMICs), respectively, totaling 240,463 for Africa. Under the retesting scenario, costs per person initially diagnosed were: $40, $21, and $42, for LICs, LMICs, and UMICs, respectively. When retesting for verification is implemented, the savings in unnecessary ART were $125, $43, and $75 per person initially diagnosed, for LICs, LMICs, and UMICs, respectively. Over the ten-year horizon, the total costs under the retesting scenario, over all country income levels, was $475 million, and was $1.192 billion under the no retesting scenario, representing total estimated savings of $717 million in HIV treatment costs averted. CONCLUSIONS: Results show that to reduce HIV misdiagnosis, countries in Africa should implement the WHO's recommendation of retesting for verification prior to ART initiation, as part of a comprehensive quality assurance program for HIV testing services. |
Scaling up testing for human immunodeficiency virus infection among contacts of index patients - 20 countries, 2016-2018
Lasry A , Medley A , Behel S , Mujawar MI , Cain M , Diekman ST , Rurangirwa J , Valverde E , Nelson R , Agolory S , Alebachew A , Auld AF , Balachandra S , Bunga S , Chidarikire T , Dao VQ , Dee J , Doumatey LEN , Dzinotyiweyi E , Dziuban EJ , Ekra KA , Fuller WB , Herman-Roloff A , Honwana NB , Khanyile N , Kim EJ , Kitenge SF , Lacson RS , Loeto P , Malamba SS , Mbayiha AH , Mekonnen A , Meselu MG , Miller LA , Mogomotsi GP , Mugambi MK , Mulenga L , Mwangi JW , Mwangi J , Nicoue AA , Nyangulu MK , Pietersen IC , Ramphalla P , Temesgen C , Vergara AE , Wei S . MMWR Morb Mortal Wkly Rep 2019 68 (21) 474-477 In 2017, the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimated that worldwide, 36.9 million persons were living with human immunodeficiency virus (HIV) infection, the virus infection that causes acquired immunodeficiency syndrome (AIDS). Among persons with HIV infection, approximately 75% were aware of their HIV status, leaving 9.4 million persons with undiagnosed infection (1). Index testing, also known as partner notification or contact tracing, is an effective case-finding strategy that targets the exposed contacts of HIV-positive persons for HIV testing services. This report summarizes data from HIV tests using index testing in 20 countries supported by CDC through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) during October 1, 2016-March 31, 2018. During this 18-month period, 1,700,998 HIV tests with 99,201 (5.8%) positive results were reported using index testing. The positivity rate for index testing was 9.8% among persons aged >/=15 years and 1.5% among persons aged <15 years. During the reporting period, HIV positivity increased 64% among persons aged >/=15 years (from 7.6% to 12.5%) and 67% among persons aged <15 years (from 1.2% to 2.0%). Expanding index testing services could help increase the number of persons with HIV infection who know their status, are initiated onto antiretroviral treatment, and consequently reduce the number of persons who can transmit the virus. |
Using a multi-test algorithm to improve the positive predictive value of rapid HIV testing and linkage to HIV care in non-clinical HIV test sites
Delaney KP , Rurangirwa J , Facente S , Dowling T , Janson M , Knoble T , Vu A , Hu YW , Kerndt P , King J , Scheer S . J Acquir Immune Defic Syndr 2015 71 (1) 78-86 BACKGROUND: Use of a rapid HIV testing algorithm (RTA) in which all tests are conducted within one client appointment could eliminate off-site confirmatory testing and reduce the number of persons not receiving confirmed results. METHODS: An RTA was implemented in 9 sites in Los Angeles and San Francisco; results of testing at these sites were compared with 23 sites conducting rapid HIV testing with off-site confirmation. RTA clients with reactive results on >1 rapid test were considered HIV+ and immediately referred for HIV care. The positive predictive value (PPV) of a single rapid HIV test and the RTA were calculated compared to laboratory-based confirmatory testing. A Poisson risk-regression model was used to assess the effect of the RTA on the proportion of HIV+ persons linked to HIV care within 90 days of a reactive rapid test. RESULTS: The PPV of the RTA was 100% compared to 86.4% for a single rapid test. The time between testing and receipt of RTA results was on average 8 days shorter than laboratory-based confirmatory testing. For risk groups other than MSM, the RTA increased the probability of being in care within 90 days compared to standard testing practice. CONCLUSIONS: The RTA increased the PPV of rapid testing to 100%, giving providers, clients, and HIV counselors timely information about a client's HIV-positive serostatus. Use of an RTA could reduce loss to follow-up between testing positive and confirmation, and increase the proportion of HIV-infected persons receiving HIV care. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure